Identification and Management of High Risk SCC Melanoma and Clearance for Transplant

Conclusions

• High-risk squamous cell carcinoma (SCC) may go undetected if high-risk features are not thoroughly examined.
• SCC can recur locally or metastasize to various body parts, with many patients showing no clinical evidence of metastatic disease at presentation.
• Staging systems are essential in identifying patients at risk for recurrence or metastasis, allowing for targeted surveillance and treatment strategies.
• Some patients with SCC may have aggressive disease that isn't apparent initially, necessitating continued surveillance and monitoring for unfindable disease.
• Immunosuppression is a significant risk factor for poorer outcomes in patients with SCC, particularly in organ transplant recipients.
• Recent advancements in staging systems and tools like the Risk app improve risk stratification for SCC and aid in clinical decision making.
• Individuals with melanoma face an increased risk of post-transplant complications, highlighting the need for careful clearance processes in transplant evaluations.
• Clear guidelines exist for assessing eligibility for transplant in patients with prior melanoma, emphasizing the significance of tumor characteristics and staging.
• The survival rates for patients on dialysis significantly vary based on their underlying conditions, with melanoma and diabetes affecting these outcomes differently.